Isbn: 9781648251696 - dealing with drugs: new histories of risk and benefit (rochester studies in medical history) (15 resultados)

ISBN
Refinar con la Búsqueda avanzada

Filtrar la búsqueda

  • Libros (15)

  • Nuevo (15)

a

Intervalo de precios personalizado (EUR)

a

  • Idioma: Inglés

    Editorial: University of Rochester Press, 2026

    1648251692 / 9781648251696

    • Tapa dura

    Librería: Kennys Bookshop and Art Galleries Ltd., Galway, GY, IrlandaKennys Bookshop and Art Galleries Ltd.

    Vendedor de 5 estrellas
    Contactar con el vendedor

    Condición: Nuevo

    EUR 112,30

    Envío por EUR 9,50 
    Se envía de Irlanda a Estados Unidos de America

    Cantidad disponible: Más de 20 disponibles

    Condición: New. 2026. hardcover. . . . . .

  • Idioma: Inglés

    Editorial: University of Rochester Press, 2026

    1648251692 / 9781648251696

    • Tapa dura

    Librería: Majestic Books, Hounslow, Reino UnidoMajestic Books

    Vendedor de 4 estrellas
    Contactar con el vendedor

    Condición: Nuevo

    EUR 136,83

    Envío por EUR 7,56 
    Se envía de Reino Unido a Estados Unidos de America

    Cantidad disponible: 3 disponibles

    Condición: New.

  • Idioma: Inglés

    Editorial: University of Rochester Press, 2026

    1648251692 / 9781648251696

    • Tapa dura

    Librería: Kennys Bookstore, Olney, MD, Estados Unidos de AmericaKennys Bookstore

    Vendedor de 5 estrellas
    Contactar con el vendedor

    Condición: Nuevo

    EUR 138,73

    Envío por EUR 9,23 
    Se envía dentro de Estados Unidos de America

    Cantidad disponible: Más de 20 disponibles

    Condición: New. 2026. hardcover. . . . . . Books ship from the US and Ireland.

  • Idioma: Inglés

    Editorial: University of Rochester Press, 2026

    1648251692 / 9781648251696

    • Tapa dura

    Librería: Books Puddle, Woodside, NY, Estados Unidos de AmericaBooks Puddle

    Vendedor de 4 estrellas
    Contactar con el vendedor

    Condición: Nuevo

    EUR 154,55

    Envío por EUR 3,51 
    Se envía dentro de Estados Unidos de America

    Cantidad disponible: 3 disponibles

    Condición: New.

  • Idioma: Inglés

    Editorial: Boydell and Brewer Ltd, US, 2026

    1648251692 / 9781648251696

    • Tapa dura

    Librería: Rarewaves.com USA, London, LONDO, Reino UnidoRarewaves.com USA

    Vendedor de 5 estrellas
    Contactar con el vendedor

    Condición: Nuevo

    EUR 177,35

     Gastos de envío gratis 
    Se envía de Reino Unido a Estados Unidos de America

    Cantidad disponible: Más de 20 disponibles

    Hardback. Condición: New. Explores how the concepts 'risk' and 'benefit' can operate as analytic tools across the medicine/drug divide, allowing new narratives, clearer understanding, and bridging the gap between licit and illicit. Scholars, like most people, tend to assume that 'pharmaceuticals' and 'illicit drugs' operate as distinct categories that should be analyzed separately from one another, as if drugs such as penicillin and cocaine are different types of objects that entail different scholarly questions, literatures, and communities of inquiry. Numerous experts have challenged this assumption by demonstrating that some 'medicines' have moved across categories as a result of criminalization; yet after decades of work, simply deconstructing the boundary is no longer fresh and compelling. It also risks continuing to center the licit/illicit divide instead of offering categories that could replace or supplement it. Dealing with Drugs: New Histories of Risk and Benefit, takes the next step: by foregrounding the rich analytic concepts 'risk' and 'benefit', chapters in this volume tell new stories about a broad group of substances that we regularly put in our bodies. Taken together, these deeply researched and innovative essays cut across inherited categories and offer a new approach to the past. In doing so, they reshape our understanding of these powerful and often dangerous chemicals. Bringing together an interdisciplinary group of scholars from Europe and North America, this volume explores the utility of risk and benefit as concepts that can bridge the worlds of pharmaceuticals and illicit drugs.

  • Idioma: Inglés

    Editorial: Boydell and Brewer, 2026

    1648251692 / 9781648251696

    • Tapa dura

    Librería: Revaluation Books, Exeter, Reino UnidoRevaluation Books

    Vendedor de 5 estrellas
    Contactar con el vendedor

    Condición: Nuevo

    EUR 194,49

    Envío por EUR 14,54 
    Se envía de Reino Unido a Estados Unidos de America

    Cantidad disponible: 2 disponibles

    Hardcover. Condición: Brand New. 398 pages. 6.00x2.00x9.00 inches. In Stock.

  • Idioma: Inglés

    Editorial: Boydell and Brewer Ltd, US, 2026

    1648251692 / 9781648251696

    • Tapa dura

    Librería: Rarewaves.com UK, London, Reino UnidoRarewaves.com UK

    Vendedor de 5 estrellas
    Contactar con el vendedor

    Condición: Nuevo

    EUR 171,32

    Envío por EUR 75,60 
    Se envía de Reino Unido a Estados Unidos de America

    Cantidad disponible: Más de 20 disponibles

    Hardback. Condición: New. Explores how the concepts 'risk' and 'benefit' can operate as analytic tools across the medicine/drug divide, allowing new narratives, clearer understanding, and bridging the gap between licit and illicit. Scholars, like most people, tend to assume that 'pharmaceuticals' and 'illicit drugs' operate as distinct categories that should be analyzed separately from one another, as if drugs such as penicillin and cocaine are different types of objects that entail different scholarly questions, literatures, and communities of inquiry. Numerous experts have challenged this assumption by demonstrating that some 'medicines' have moved across categories as a result of criminalization; yet after decades of work, simply deconstructing the boundary is no longer fresh and compelling. It also risks continuing to center the licit/illicit divide instead of offering categories that could replace or supplement it. Dealing with Drugs: New Histories of Risk and Benefit, takes the next step: by foregrounding the rich analytic concepts 'risk' and 'benefit', chapters in this volume tell new stories about a broad group of substances that we regularly put in our bodies. Taken together, these deeply researched and innovative essays cut across inherited categories and offer a new approach to the past. In doing so, they reshape our understanding of these powerful and often dangerous chemicals. Bringing together an interdisciplinary group of scholars from Europe and North America, this volume explores the utility of risk and benefit as concepts that can bridge the worlds of pharmaceuticals and illicit drugs.

  • Idioma: Inglés

    Editorial: Boydell & Brewer Ltd, Rochester, 2026

    1648251692 / 9781648251696

    • Tapa dura
    • Impresión bajo demanda

    Librería: AussieBookSeller, Truganina, VIC, AustraliaAussieBookSeller

    Vendedor de 5 estrellas
    Contactar con el vendedor

    Condición: Nuevo

    EUR 90,85

    Envío por EUR 32,51 
    Se envía de Australia a Estados Unidos de America

    Cantidad disponible: 1 disponibles

    Hardcover. Condición: new. Hardcover. Explores how the concepts 'risk' and 'benefit' can operate as analytic tools across the medicine/drug divide, allowing new narratives, clearer understanding, and bridging the gap between licit and illicit.Scholars, like most people, tend to assume that 'pharmaceuticals' and 'illicit drugs' operate as distinct categories that should be analyzed separately from one another, as if drugs such as penicillin and cocaine are different types of objects that entail different scholarly questions, literatures, and communities of inquiry. Numerous experts have challenged this assumption by demonstrating that some 'medicines' have moved across categories as a result of criminalization; yet after decades of work, simply deconstructing the boundary is no longer fresh and compelling. It also risks continuing to center the licit/illicit divide instead of offering categories that could replace or supplement it.Dealing with Drugs: New Histories of Risk and Benefit, takes the next step: by foregrounding the rich analytic concepts 'risk' and 'benefit', chapters in this volume tell new stories about a broad group of substances that we regularly put in our bodies. Taken together, these deeply researched and innovative essays cut across inherited categories and offer a new approach to the past. In doing so, they reshape our understanding of these powerful and often dangerous chemicals. Bringing together an interdisciplinary group of scholars from Europe and North America, this volume explores the utility of risk and benefit as concepts that can bridge the worlds of pharmaceuticals and illicit drugs. Explores how the concepts 'risk' and 'benefit' can operate as analytic tools across the medicine/drug divide, allowing new narratives, clearer understanding, and bridging the gap between licit and illicit. This item is printed on demand. Shipping may be from our Sydney, NSW warehouse or from our UK or US warehouse, depending on stock availability.

  • Idioma: Inglés

    Editorial: Boydell and Brewer, 2026

    1648251692 / 9781648251696

    • Tapa dura
    • Impresión bajo demanda

    Librería: Revaluation Books, Exeter, Reino UnidoRevaluation Books

    Vendedor de 5 estrellas
    Contactar con el vendedor

    Condición: Nuevo

    EUR 116,16

    Envío por EUR 14,54 
    Se envía de Reino Unido a Estados Unidos de America

    Cantidad disponible: 2 disponibles

    Hardcover. Condición: Brand New. 398 pages. 6.00x2.00x9.00 inches. In Stock. This item is printed on demand.

  • Idioma: Inglés

    Editorial: Boydell & Brewer Ltd, Rochester, 2026

    1648251692 / 9781648251696

    • Tapa dura
    • Impresión bajo demanda

    Librería: Grand Eagle Retail, Bensenville, IL, Estados Unidos de AmericaGrand Eagle Retail

    Vendedor de 5 estrellas
    Contactar con el vendedor

    Condición: Nuevo

    EUR 160,64

     Gastos de envío gratis 
    Se envía dentro de Estados Unidos de America

    Cantidad disponible: 1 disponibles

    Hardcover. Condición: new. Hardcover. Explores how the concepts 'risk' and 'benefit' can operate as analytic tools across the medicine/drug divide, allowing new narratives, clearer understanding, and bridging the gap between licit and illicit.Scholars, like most people, tend to assume that 'pharmaceuticals' and 'illicit drugs' operate as distinct categories that should be analyzed separately from one another, as if drugs such as penicillin and cocaine are different types of objects that entail different scholarly questions, literatures, and communities of inquiry. Numerous experts have challenged this assumption by demonstrating that some 'medicines' have moved across categories as a result of criminalization; yet after decades of work, simply deconstructing the boundary is no longer fresh and compelling. It also risks continuing to center the licit/illicit divide instead of offering categories that could replace or supplement it.Dealing with Drugs: New Histories of Risk and Benefit, takes the next step: by foregrounding the rich analytic concepts 'risk' and 'benefit', chapters in this volume tell new stories about a broad group of substances that we regularly put in our bodies. Taken together, these deeply researched and innovative essays cut across inherited categories and offer a new approach to the past. In doing so, they reshape our understanding of these powerful and often dangerous chemicals. Bringing together an interdisciplinary group of scholars from Europe and North America, this volume explores the utility of risk and benefit as concepts that can bridge the worlds of pharmaceuticals and illicit drugs. Explores how the concepts 'risk' and 'benefit' can operate as analytic tools across the medicine/drug divide, allowing new narratives, clearer understanding, and bridging the gap between licit and illicit. This item is printed on demand. Shipping may be from multiple locations in the US or from the UK, depending on stock availability.

  • Idioma: Inglés

    Editorial: University of Rochester Press, 2026

    1648251692 / 9781648251696

    • Tapa dura
    • Impresión bajo demanda

    Librería: moluna, Greven, Alemaniamoluna

    Vendedor de 5 estrellas
    Contactar con el vendedor

    Condición: Nuevo

    EUR 128,11

    Envío por EUR 48,99 
    Se envía de Alemania a Estados Unidos de America

    Cantidad disponible: Más de 20 disponibles

    Condición: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt.

  • Idioma: Inglés

    Editorial: Boydell & Brewer Ltd, Rochester, 2026

    1648251692 / 9781648251696

    • Tapa dura
    • Impresión bajo demanda

    Librería: CitiRetail, Stevenage, Reino UnidoCitiRetail

    Vendedor de 5 estrellas
    Contactar con el vendedor

    Condición: Nuevo

    EUR 146,74

    Envío por EUR 43,04 
    Se envía de Reino Unido a Estados Unidos de America

    Cantidad disponible: 1 disponibles

    Hardcover. Condición: new. Hardcover. Explores how the concepts 'risk' and 'benefit' can operate as analytic tools across the medicine/drug divide, allowing new narratives, clearer understanding, and bridging the gap between licit and illicit.Scholars, like most people, tend to assume that 'pharmaceuticals' and 'illicit drugs' operate as distinct categories that should be analyzed separately from one another, as if drugs such as penicillin and cocaine are different types of objects that entail different scholarly questions, literatures, and communities of inquiry. Numerous experts have challenged this assumption by demonstrating that some 'medicines' have moved across categories as a result of criminalization; yet after decades of work, simply deconstructing the boundary is no longer fresh and compelling. It also risks continuing to center the licit/illicit divide instead of offering categories that could replace or supplement it.Dealing with Drugs: New Histories of Risk and Benefit, takes the next step: by foregrounding the rich analytic concepts 'risk' and 'benefit', chapters in this volume tell new stories about a broad group of substances that we regularly put in our bodies. Taken together, these deeply researched and innovative essays cut across inherited categories and offer a new approach to the past. In doing so, they reshape our understanding of these powerful and often dangerous chemicals. Bringing together an interdisciplinary group of scholars from Europe and North America, this volume explores the utility of risk and benefit as concepts that can bridge the worlds of pharmaceuticals and illicit drugs. Explores how the concepts 'risk' and 'benefit' can operate as analytic tools across the medicine/drug divide, allowing new narratives, clearer understanding, and bridging the gap between licit and illicit. This item is printed on demand. Shipping may be from our UK warehouse or from our Australian or US warehouses, depending on stock availability.

  • Idioma: Inglés

    Editorial: University of Rochester Press, 2026

    1648251692 / 9781648251696

    • Tapa dura
    • Impresión bajo demanda

    Librería: Biblios, frankfurt am main, HESSE, AlemaniaBiblios

    Vendedor de 4 estrellas
    Contactar con el vendedor

    Condición: Nuevo

    EUR 193,28

    Envío por EUR 9,95 
    Se envía de Alemania a Estados Unidos de America

    Cantidad disponible: 4 disponibles

    Condición: New. PRINT ON DEMAND.

  • Idioma: Inglés

    Editorial: University of Rochester Press, 2026

    1648251692 / 9781648251696

    • Tapa dura
    • Impresión bajo demanda

    Librería: preigu, Osnabrück, Alemaniapreigu

    Vendedor de 5 estrellas
    Contactar con el vendedor

    Condición: Nuevo

    EUR 132,85

    Envío por EUR 70,00 
    Se envía de Alemania a Estados Unidos de America

    Cantidad disponible: 5 disponibles

    Buch. Condición: Neu. Dealing with Drugs | New Histories of Risk and Benefit | David David Herzberg (u. a.) | Buch | Einband - fest (Hardcover) | Englisch | 2026 | University of Rochester Press | EAN 9781648251696 | Verantwortliche Person für die EU: Libri GmbH, Europaallee 1, 36244 Bad Hersfeld, gpsr[at]libri[dot]de | Anbieter: preigu Print on Demand.

  • Idioma: Inglés

    Editorial: University Of Rochester Press, 2026

    1648251692 / 9781648251696

    • Tapa dura
    • Impresión bajo demanda

    Librería: AHA-BUCH GmbH, Einbeck, AlemaniaAHA-BUCH GmbH

    Vendedor de 5 estrellas
    Contactar con el vendedor

    Condición: Nuevo

    EUR 278,60

    Envío por EUR 35,00 
    Se envía de Alemania a Estados Unidos de America

    Cantidad disponible: 1 disponibles

    Buch. Condición: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Explores how the concepts 'risk' and 'benefit' can operate as analytic tools across the medicine/drug divide, allowing new narratives, clearer understanding, and bridging the gap between licit and illicit.Scholars, like most people, tend to assume that 'pharmaceuticals' and 'illicit drugs' operate as distinct categories that should be analyzed separately from one another, as if drugs such as penicillin and cocaine are different types of objects that entail different scholarly questions, literatures, and communities of inquiry. Numerous experts have challenged this assumption by demonstrating that some 'medicines' have moved across categories as a result of criminalization; yet after decades of work, simply deconstructing the boundary is no longer fresh and compelling. It also risks continuing to center the licit/illicit divide instead of offering categories that could replace or supplement it. Dealing with Drugs: New Histories of Risk and Benefit, takes the next step: by foregrounding the rich analytic concepts 'risk' and 'benefit', chapters in this volume tell new stories about a broad group of substances that we regularly put in our bodies. Taken together, these deeply researched and innovative essays cut across inherited categories and offer a new approach to the past. In doing so, they reshape our understanding of these powerful and often dangerous chemicals. Bringing together an interdisciplinary group of scholars from Europe and North America, this volume explores the utility of risk and benefit as concepts that can bridge the worlds of pharmaceuticals and illicit drugs.